8 September 2021 - Researchers and policy makers in the US are exploring the implementation of health technology assessment and value based pricing to negotiate drug prices and limit spending.
Objections made to the quality-adjusted life year (QALY), the most frequently used health economic outcome for such assessments, are a barrier to the adoption of these tools.
This literature review identifies and addresses the range of criticisms made against QALYs.